IL163720A0 - Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents - Google Patents

Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents

Info

Publication number
IL163720A0
IL163720A0 IL16372003A IL16372003A IL163720A0 IL 163720 A0 IL163720 A0 IL 163720A0 IL 16372003 A IL16372003 A IL 16372003A IL 16372003 A IL16372003 A IL 16372003A IL 163720 A0 IL163720 A0 IL 163720A0
Authority
IL
Israel
Prior art keywords
migraine
therapy
treatment
agents
anticonvulsant derivatives
Prior art date
Application number
IL16372003A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of IL163720A0 publication Critical patent/IL163720A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16372003A 2002-02-26 2003-02-25 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents IL163720A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35989402P 2002-02-26 2002-02-26
PCT/US2003/005463 WO2003072138A1 (en) 2002-02-26 2003-02-25 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents

Publications (1)

Publication Number Publication Date
IL163720A0 true IL163720A0 (en) 2005-12-18

Family

ID=27663315

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16372003A IL163720A0 (en) 2002-02-26 2003-02-25 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
IL163720A IL163720A (en) 2002-02-26 2004-08-24 Use of topiramate for the preparation of a medicament suitable for co-therapy with a triptan

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL163720A IL163720A (en) 2002-02-26 2004-08-24 Use of topiramate for the preparation of a medicament suitable for co-therapy with a triptan

Country Status (18)

Country Link
US (2) US20030225002A1 (cg-RX-API-DMAC7.html)
EP (1) EP1478400A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005518439A (cg-RX-API-DMAC7.html)
KR (1) KR101008326B1 (cg-RX-API-DMAC7.html)
CN (1) CN100352506C (cg-RX-API-DMAC7.html)
AU (1) AU2003213242A1 (cg-RX-API-DMAC7.html)
BR (1) BR0307951A (cg-RX-API-DMAC7.html)
CA (1) CA2419989A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20040846A2 (cg-RX-API-DMAC7.html)
IL (2) IL163720A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04008259A (cg-RX-API-DMAC7.html)
NO (1) NO20043984L (cg-RX-API-DMAC7.html)
NZ (1) NZ534874A (cg-RX-API-DMAC7.html)
PL (1) PL372393A1 (cg-RX-API-DMAC7.html)
RU (1) RU2004126093A (cg-RX-API-DMAC7.html)
UA (1) UA81110C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003072138A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200407729B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
JP2007523176A (ja) * 2004-02-17 2007-08-16 セプラコア インコーポレーテッド シタロプラム、エスシタロプラム又はシタロプラム代謝物質を用いる片頭痛又は頭痛疾患の治療又は病気の予防法
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
FR2890564B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
WO2007120747A2 (en) * 2006-04-13 2007-10-25 Nupathe Inc. Transdermal methods and systems for the delivery of anti-migraine compounds
EP2023894A4 (en) * 2006-04-25 2010-10-20 Applied Pharma Res FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
EP2363113B1 (en) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
BRPI0918623A2 (pt) * 2008-09-17 2015-12-01 Hannover Med Hochschule métodos e kits para tratar distúrbios de cefaleia em grupo
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
WO2018067330A1 (en) * 2016-10-06 2018-04-12 Baylor College Of Medicine Photochromatic modulation with fluorescein for the treatment of photo-oculodynia and blepharospasm
DK3955933T3 (da) * 2019-04-15 2024-02-12 Vistagen Therapeutics Inc Behandling af migræne

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
DE69733081T2 (de) * 1996-08-23 2006-05-11 Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
EP0957928A1 (fr) * 1997-03-03 1999-11-24 Laboratoires Remilea Compositions d'extraits de plantes, leur procede de preparation, et compositions pharmaceutiques les renfermant
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
GB9720270D0 (en) * 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
US6068999A (en) * 1998-06-25 2000-05-30 Hendrix; Curt Dietary supplement for supporting cerebrovascular tone and treating migraine headaches
CN1182845C (zh) * 1999-01-19 2005-01-05 奥索-麦克尼尔药品公司 用于治疗集束性头痛的抗惊厥剂衍生物
EP1210118B1 (en) * 1999-08-20 2004-12-08 Ortho-McNeil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug

Also Published As

Publication number Publication date
CN100352506C (zh) 2007-12-05
EP1478400A1 (en) 2004-11-24
CN1646168A (zh) 2005-07-27
RU2004126093A (ru) 2005-04-10
IL163720A (en) 2012-06-28
JP2005518439A (ja) 2005-06-23
US20030225002A1 (en) 2003-12-04
NO20043984L (no) 2004-09-23
PL372393A1 (en) 2005-07-25
NZ534874A (en) 2007-03-30
MXPA04008259A (es) 2005-05-27
AU2003213242A1 (en) 2003-09-09
KR20040091074A (ko) 2004-10-27
ZA200407729B (en) 2006-06-28
BR0307951A (pt) 2004-12-21
WO2003072138A1 (en) 2003-09-04
UA81110C2 (en) 2007-12-10
HRP20040846A2 (en) 2005-06-30
KR101008326B1 (ko) 2011-01-13
US20070099849A1 (en) 2007-05-03
HK1080731A1 (en) 2006-05-04
CA2419989A1 (en) 2003-08-05

Similar Documents

Publication Publication Date Title
PL372393A1 (en) Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and antimigraine agents
AU2003286567A8 (en) Methods for the treatment of skin disorders
EP1549614A4 (en) VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
PT2308507E (pt) Métodos de tratamento de pré-eclâmpsia
PT1530466E (pt) Utilização de nintedanib para o tratamento de fibrose pulmonar
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
IL136960A0 (en) Combination therapy for the treatment of migraine
IL159879A0 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
AU2003251875A8 (en) Combination therapy for the treatment of neoplasms
GB2408558B (en) Treatment of pipes
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
AP2004003174A0 (en) Treatment of water
GB0210264D0 (en) The treatment of pain and migraine headache
GB0210741D0 (en) Methods of therapy
AU2001285156A1 (en) Combination therapy for the treatment of migraine
EP1539100A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
AU2003270615A8 (en) Treatment of steatosis using hyperthermia
IL136962A0 (en) Combination therapy for the treatment of migraine
IL136025A0 (en) Combination therapy for the treatment of migraine
EP1573063A4 (en) TREATMENT OF LIVER DISEASES
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
IL136024A0 (en) Combination therapy for the treatment of migraine
PT1451177E (pt) Derivados substituídos de 2-pirrolidin-2-1l-1h-indole para o tratamento da enxaqueca.
GB0221712D0 (en) Methods of treatment
GB0400094D0 (en) The method of treating tuberculosis